Abstract
Dyslipidaemia i s a significant clinical problem, especially in relation to the prognosis of patients. Thus, pro perly adjusted hypolipidemic treatment can substantially affect not on ly morbidity but also mortality.
Patients not adequately responding to monotherapy with available hypolipidemics (mostly statins) are offered their fixed combinations. Such combination is rosuvastatin plus ezetimibe.
A summary of its therapeutic benefit with reference to clinical data is the subject of this review article.